|
|
|
| The influence of cyclosporine for treating women with high-risk of preeclampsia on their inflammatory factors and outcomes |
| Kaifeng Maternal and Child Health Care Hospital (Kaifeng Key Laboratory of Reproductive Endocrinology), Henan Province, 47500 |
|
|
|
|
Abstract To explore the influence of cyclosporine for treating pregnant women with high-risk of preeclampsia (PE) on their inflammatory factors and outcomes. Methods: 60 pregnant women with high-risk of PE were selected as the research objects, and were divided into group A (30 women given regular pregnancy guidance) and group B (30 women given cyclosporine except to regular pregnancy guidance) according to the random number table from February 2019 to May 2020. The liver and kidney function and inflammatory factors of the women before treatment and postpartum were compared between the two groups. The incidences of PE, adverse maternal and infant outcomes, and drug safety of the women in the two groups were counted. Results: The levels of blood urea nitrogen (BUN), blood creatinine (SCr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), interleukin-6 (IL-6), tumor necrosis factor-α(TTNF-α), and γ-interferon (IFN-γ) of the postpartum women in the two groups had decreased significantly, and the changes of which of the women in group B were significant lower than those of the women in group A (P<0.05). The incidences of PE (6.7%) and maternal and infant adverse outcomes (26.7%) of the women in group B were significant lower than those of the women in group A (P<0.05). There was no any woman with serious adverse reaction in the two groups. Conclusion: Cyclosporine treating pregnant women with high risk of PE can effectively improve their liver and kidney function and the levels of inflammatory factors, reduce the incidence of PE, improve pregnancy outcomes with good safety.
|
|
|
|
|
|
|
|
|
